Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays that the study is no longer enrolling participants and that results have been submitted. It also adds new navigation/help items (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label (from 'Intervention / Treatment' to 'Intervention/Treatment') with a revision tag updated to v3.6.0.SummaryDifference0.5%

- Check8 days agoChange DetectedThe study record now displays Revision: v3.5.5, replacing Revision: v3.5.4, signaling a small update to the page data. This appears to be an administrative update rather than a change to study content or outcomes.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedEntries were added to the Study Record Dates section to capture the latest submission and posting dates, as well as a completion date. These updates reflect the current activity and status of the study record.SummaryDifference0.3%

- Check30 days agoChange DetectedRevision metadata on the page was updated from v3.5.3 to v3.5.4, reflecting a routine update to the page version.SummaryDifference0.1%

- Check37 days agoChange DetectedThe study status is updated to Completed with a completion date of 2026-04-30 and a last update date of 2026-05-01, and the previous 'Active, not recruiting' status has been removed.SummaryDifference0.5%

- Check51 days agoChange DetectedThe page’s interface/build version was updated from v3.5.2 to v3.5.3 without changing the displayed study details.SummaryDifference0.1%

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.